139 related articles for article (PubMed ID: 22932002)
1. Analysis of the factors motivating HCV-infected patients to accept interferon therapy.
Nagao Y; Sata M
BMC Res Notes; 2012 Aug; 5():470. PubMed ID: 22932002
[TBL] [Abstract][Full Text] [Related]
2. Development and exacerbation of oral lichen planus during and after interferon therapy for hepatitis C.
Nagao Y; Sata M; Ide T; Suzuki H; Tanikawa K; Itoh K; Kameyama T
Eur J Clin Invest; 1996 Dec; 26(12):1171-4. PubMed ID: 9013095
[TBL] [Abstract][Full Text] [Related]
3. Candidiasis and other oral mucosal lesions during and after interferon therapy for HCV-related chronic liver diseases.
Nagao Y; Hashimoto K; Sata M
BMC Gastroenterol; 2012 Nov; 12():155. PubMed ID: 23122361
[TBL] [Abstract][Full Text] [Related]
4. Exacerbation of oral erosive lichen planus by combination of interferon and ribavirin therapy for chronic hepatitis C.
Nagao Y; Kawaguchi T; Ide T; Kumashiro R; Sata M
Int J Mol Med; 2005 Feb; 15(2):237-41. PubMed ID: 15647837
[TBL] [Abstract][Full Text] [Related]
5. [Clinical evaluation in oral lichen planus with chronic hepatitis C: the role of interferon treatment].
Sugiyama T; Shimizu M; Ohnishi H; Noguchi N; Iwata K; Kojima Y; Watanabe Y; Kawase K; Fukutomi Y; Yamauchi O; Yasuda S; Yamada M; Kobayashi S; Kojima M
Nihon Shokakibyo Gakkai Zasshi; 2000 May; 97(5):568-74. PubMed ID: 10846411
[TBL] [Abstract][Full Text] [Related]
6. Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group.
Mashiba T; Joko K; Kurosaki M; Ochi H; Osaki Y; Kojima Y; Nakata R; Goto T; Takehiro A; Kimura H; Mitsuda A; Kawanami C; Uchida Y; Ogawa C; Kusakabe A; Narita R; Ide Y; Abe T; Tsuji K; Kitamura T; Okada K; Sohda T; Shigeno M; Satou T; Izumi N
PLoS One; 2018; 13(4):e0194704. PubMed ID: 29659591
[TBL] [Abstract][Full Text] [Related]
7. Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis C virus in Japan.
Toyoda H; Tada T; Takaguchi K; Senoh T; Shimada N; Hiraoka A; Michitaka K; Ishikawa T; Kumada T
J Viral Hepat; 2017 Jun; 24(6):472-476. PubMed ID: 27983762
[TBL] [Abstract][Full Text] [Related]
8. Analysis of factors interfering with the acceptance of interferon therapy by HCV-infected patients.
Nagao Y; Kawakami Y; Yoshiyama T; Sata M
Med Sci Monit; 2008 Nov; 14(11):PI45-52. PubMed ID: 18971882
[TBL] [Abstract][Full Text] [Related]
9. Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor.
Kanogawa N; Ogasawara S; Chiba T; Saito T; Motoyama T; Suzuki E; Ooka Y; Tawada A; Kanda T; Mikami S; Azemoto R; Kaiho T; Shinozaki M; Ohtsuka M; Miyazaki M; Yokosuka O
J Gastroenterol Hepatol; 2015 Jul; 30(7):1197-204. PubMed ID: 25682720
[TBL] [Abstract][Full Text] [Related]
10. Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study.
Nagaoki Y; Aikata H; Nakano N; Shinohara F; Nakamura Y; Hatooka M; Morio K; Kan H; Fujino H; Kobayashi T; Fukuhara T; Masaki K; Ono A; Nakahara T; Kawaoka T; Miki D; Tsuge M; Hiramatsu A; Imamura M; Takahashi S; Kawakami Y; Ochi H; Chayama K;
J Gastroenterol Hepatol; 2016 May; 31(5):1009-15. PubMed ID: 26584407
[TBL] [Abstract][Full Text] [Related]
11. Effect of sustained virological response to interferon therapy for hepatitis C to the hepatectomy for primary hepatocellular carcinoma.
Tsujita E; Maeda T; Kayashima H; Harada N; Tsutsui S; Matsuda H; Kinjo N; Ikeda Y; Morita M; Ishida T
Hepatogastroenterology; 2015; 62(137):157-63. PubMed ID: 25911888
[TBL] [Abstract][Full Text] [Related]
12. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.
Bruno S; Di Marco V; Iavarone M; Roffi L; Boccaccio V; Crosignani A; Cabibbo G; Rossi S; Calvaruso V; Aghemo A; Giacomelli L; Craxì A; Colombo M; Maisonneuve P
Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617
[TBL] [Abstract][Full Text] [Related]
13. Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon.
Petta S; Cabibbo G; Barbara M; Attardo S; Bucci L; Farinati F; Giannini EG; Tovoli F; Ciccarese F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Sacco R; Virdone R; Marra F; Felder M; Morisco F; Benvegnù L; Gasbarrini A; Svegliati-Baroni G; Foschi FG; Olivani A; Masotto A; Nardone G; Colecchia A; Persico M; Boccaccio V; Craxì A; Bruno S; Trevisani F; Cammà C;
Aliment Pharmacol Ther; 2017 Jan; 45(1):160-168. PubMed ID: 27790734
[TBL] [Abstract][Full Text] [Related]
14. Second hepatectomy for recurrent hepatocellular carcinoma achieved sustained virological response to interferon therapy for hepatitis C.
Tsujita E; Yamashita Y; Takeishi K; Maeda T; Takaki S; Mori N; Aisaka Y; Furukawa Y; Shirabe K; Ishida T; Maehara Y
Hepatogastroenterology; 2013; 60(128):2048-54. PubMed ID: 24088310
[TBL] [Abstract][Full Text] [Related]
15. Effect of previous interferon treatment on outcome after curative treatment for hepatitis C virus-related hepatocellular carcinoma.
Miyatake H; Kobayashi Y; Iwasaki Y; Nakamura S; Ohnishi H; Kuwaki K; Toshimori J; Hagihara H; Nouso K; Yamamoto K
Dig Dis Sci; 2012 Apr; 57(4):1092-101. PubMed ID: 21989822
[TBL] [Abstract][Full Text] [Related]
16. Persistent Hepatic Inflammation Plays a Role in Hepatocellular Carcinoma After Sustained Virological Response in Patients with HCV Infection.
Nirei K; Kanda T; Nakamura H; Matsuoka S; Takayama T; Sugitani M; Moriyama M
Int J Med Sci; 2018; 15(5):466-474. PubMed ID: 29559835
[No Abstract] [Full Text] [Related]
17. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.
Yamada G; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
Clin Drug Investig; 2008; 28(1):9-16. PubMed ID: 18081356
[TBL] [Abstract][Full Text] [Related]
18. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy.
Nagaoki Y; Imamura M; Nishida Y; Daijo K; Teraoka Y; Honda F; Nakamura Y; Morio K; Fujino H; Nakahara T; Kawaoka T; Tsuge M; Hiramatsu A; Kawakami Y; Miki D; Hiyama Y; Ochi H; Chayama K; Aikata H
J Med Virol; 2019 Apr; 91(4):650-658. PubMed ID: 30381831
[TBL] [Abstract][Full Text] [Related]
19. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.
Nahon P; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; Di Martino V; Sutton A; Roudot-Thoraval F; Audureau E;
Gastroenterology; 2018 Nov; 155(5):1436-1450.e6. PubMed ID: 30031138
[TBL] [Abstract][Full Text] [Related]
20. Successful Treatment of Hepatitis C Virus-associated Oral Lichen Planus by Interferon-free Therapy with Direct-acting Antivirals.
Nagao Y; Kimura K; Kawahigashi Y; Sata M
Clin Transl Gastroenterol; 2016 Jul; 7(7):e179. PubMed ID: 27388424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]